Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Short term Debt (2016 - 2025)

Mesa Laboratories' Short term Debt history spans 11 years, with the latest figure at $4.7 million for Q3 2025.

  • On a quarterly basis, Short term Debt fell 95.17% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 95.17% decrease, with the full-year FY2025 number at $3.8 million, changed N/A from a year prior.
  • Short term Debt hit $4.7 million in Q3 2025 for Mesa Laboratories, up from $4.2 million in the prior quarter.
  • Over the last five years, Short term Debt for MLAB hit a ceiling of $97.0 million in Q3 2024 and a floor of $235000.0 in Q1 2021.
  • Historically, Short term Debt has averaged $16.8 million across 3 years, with a median of $3.8 million in 2024.
  • The widest YoY moves for Short term Debt: up 12.51% in 2025, down 95.17% in 2025.
  • Tracing MLAB's Short term Debt over 3 years: stood at $235000.0 in 2021, then skyrocketed by 1495.74% to $3.8 million in 2024, then rose by 25.01% to $4.7 million in 2025.
  • Business Quant data shows Short term Debt for MLAB at $4.7 million in Q3 2025, $4.2 million in Q2 2025, and $3.8 million in Q1 2025.